Lori Kunkel

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.

Maverick Therapeutics is now part of Takeda. Follow us at https://www.linkedin.com/company/takeda-pharmaceuticals/ Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Maverick’s highly innovative platform, COBRA™, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.

Amphivena Therapeutics Inc is a privately held immuno-oncology company based in SSF, that is developing selective T cell engagers for treatment of hematological and solid tumors. AMV564, our lead molecule, has demonstrated novel clinical activity in rapidly and selectively eliminating leukemic blasts in AML and granulocytic/monocytic MDSCs while sparing normal myeloid cells, providing a unique opportunity to explore the impact of depleting MDSCs in cancers.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. For more information, please visit www.harpoontx.com.

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients. Loxo@Lilly is a global organization with team members in Boulder, Colorado; Indianapolis, Indiana; New York City, New York; San Diego, California; South San Francisco, California; Stamford, Connecticut; and Madrid, Spain.

Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.

Maverick Therapeutics is now part of Takeda. Follow us at https://www.linkedin.com/company/takeda-pharmaceuticals/ Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Maverick’s highly innovative platform, COBRA™, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.

Amphivena Therapeutics Inc is a privately held immuno-oncology company based in SSF, that is developing selective T cell engagers for treatment of hematological and solid tumors. AMV564, our lead molecule, has demonstrated novel clinical activity in rapidly and selectively eliminating leukemic blasts in AML and granulocytic/monocytic MDSCs while sparing normal myeloid cells, providing a unique opportunity to explore the impact of depleting MDSCs in cancers.

Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer. For more information, please visit www.harpoontx.com.

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients. Loxo@Lilly is a global organization with team members in Boulder, Colorado; Indianapolis, Indiana; New York City, New York; San Diego, California; South San Francisco, California; Stamford, Connecticut; and Madrid, Spain.